2026 Global: Cell Isolation Market-Competitive Review (2032) report
Description
The 2026 Global: Cell Isolation Market-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cell isolation market by geography and historical trend. The scope of the report extends to sizing of the cell isolation market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Thermo Fisher Scientific, Becton Dickinson and Company (BD), Danaher Corporation (including Beckman Coulter and Cytiva), Merck KGaA (MilliporeSigma), and Bio-Rad Laboratories dominate the cell isolation market, alongside Miltenyi Biotec, STEMCELL Technologies, Terumo Corporation, GE Healthcare, and Agilent Technologies as the ten major players. These companies control over 60% of the market share through advanced technologies like magnetic-activated cell sorting (MACS), fluorescence-activated cell sorting (FACS), and microfluidics, driving growth in personalized medicine, regenerative therapies, and oncology research. Thermo Fisher Scientific leads with comprehensive instruments, consumables, and reagents for centrifugation and MACS, bolstered by its 2025 acquisition of Solventum’s purification unit for $4.1 billion to enhance filtration capabilities. BD excels in spectral flow cytometry, launching the FACSDiscover A8 in May 2025 for 50-parameter analysis and merging with Waters for $17.5 billion in July 2025 to integrate diagnostics platforms. Danaher, via Beckman Coulter, provides centrifugation and flow systems, while its February 2025 acquisition of Precision Nanosystems strengthens lipid-nanoparticle tech for cell therapies.
Merck KGaA, operating as MilliporeSigma, commands significant share with filtration and MACS innovations, including a $600 million Mirus Bio purchase for reagent security, supporting high-purity isolation for biopharma workflows. Bio-Rad Laboratories offers density gradient media and low-to-mid throughput reagents, catering to academic labs and expanding in single-cell omics. Miltenyi Biotec pioneered MACS, holding strong in immunology and stem cell research with scalable, clinical-grade protocols that capture 38-45% technique market share. STEMCELL Technologies specializes in stem cell kits and culture reagents, leading preclinical and GMP workflows for fragile cells in regenerative medicine. Terumo Corporation (Terumo BCT) focuses on apheresis and processing systems, launching a Therapy Innovations unit in November 2024 for cell therapy manufacturing.
GE Healthcare (under Danaher influence via Cytiva) provides separation tools integrated into bioprocessing, while Agilent Technologies delivers analytical solutions for precise cell profiling. These firms employ strategies like vertical integration, partnerships, and automation—such as BD's robotic alliances and Cytek's filterless profiling—to address high costs and technical challenges, fueling a market projected to reach $25.4-30.14 billion by 2030-2034 at 9.9-13.85% CAGR. North America holds 40.8-60% share due to NIH funding and FDA approvals, with Asia-Pacific growing fastest via biotech investments. Innovations in AI, single-cell analysis, and consumables (65% segment share) sustain their edge amid rising chronic disease prevalence and cell therapy trials.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cell isolation market by geography and historical trend. The scope of the report extends to sizing of the cell isolation market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Thermo Fisher Scientific, Becton Dickinson and Company (BD), Danaher Corporation (including Beckman Coulter and Cytiva), Merck KGaA (MilliporeSigma), and Bio-Rad Laboratories dominate the cell isolation market, alongside Miltenyi Biotec, STEMCELL Technologies, Terumo Corporation, GE Healthcare, and Agilent Technologies as the ten major players. These companies control over 60% of the market share through advanced technologies like magnetic-activated cell sorting (MACS), fluorescence-activated cell sorting (FACS), and microfluidics, driving growth in personalized medicine, regenerative therapies, and oncology research. Thermo Fisher Scientific leads with comprehensive instruments, consumables, and reagents for centrifugation and MACS, bolstered by its 2025 acquisition of Solventum’s purification unit for $4.1 billion to enhance filtration capabilities. BD excels in spectral flow cytometry, launching the FACSDiscover A8 in May 2025 for 50-parameter analysis and merging with Waters for $17.5 billion in July 2025 to integrate diagnostics platforms. Danaher, via Beckman Coulter, provides centrifugation and flow systems, while its February 2025 acquisition of Precision Nanosystems strengthens lipid-nanoparticle tech for cell therapies.
Merck KGaA, operating as MilliporeSigma, commands significant share with filtration and MACS innovations, including a $600 million Mirus Bio purchase for reagent security, supporting high-purity isolation for biopharma workflows. Bio-Rad Laboratories offers density gradient media and low-to-mid throughput reagents, catering to academic labs and expanding in single-cell omics. Miltenyi Biotec pioneered MACS, holding strong in immunology and stem cell research with scalable, clinical-grade protocols that capture 38-45% technique market share. STEMCELL Technologies specializes in stem cell kits and culture reagents, leading preclinical and GMP workflows for fragile cells in regenerative medicine. Terumo Corporation (Terumo BCT) focuses on apheresis and processing systems, launching a Therapy Innovations unit in November 2024 for cell therapy manufacturing.
GE Healthcare (under Danaher influence via Cytiva) provides separation tools integrated into bioprocessing, while Agilent Technologies delivers analytical solutions for precise cell profiling. These firms employ strategies like vertical integration, partnerships, and automation—such as BD's robotic alliances and Cytek's filterless profiling—to address high costs and technical challenges, fueling a market projected to reach $25.4-30.14 billion by 2030-2034 at 9.9-13.85% CAGR. North America holds 40.8-60% share due to NIH funding and FDA approvals, with Asia-Pacific growing fastest via biotech investments. Innovations in AI, single-cell analysis, and consumables (65% segment share) sustain their edge amid rising chronic disease prevalence and cell therapy trials.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.